About
Salignostics develops fast, safe, user-friendly, and cost-effective saliva-based diagnostic solutions. Its cutting-edge technology processes saliva into an analyzable body fluid, offering fast, safe, user-friendly, and cost-effective diagnostic options for self-testing, homecare, point-of-care, and laboratory settings. This addresses the limitations of current diagnostic methods which are expensive, time-consuming, and personnel dependent. Our products facilitate easy saliva self-collection, sample preparation, and rapid detection of a wide array of analytes and biomarkers in a single device. The device can identify human proteins, viral proteins, DNA, and RNA, with the ability to detect a high number of previously unidentifiable biomarkers. This enables non-invasive and painless diagnostics at home. Salignostics holds 4 innovative patents and 2 trade secrets covering its platform technology. The possibility to collect, detect, and test positions us to address a large group of multi-billion-dollar markets, including the home diagnostics market, projected to grow to $10B by 2032. In 2023, we have successfully launched Salistick, the first rapid saliva-based pregnancy test, already available in the UK, Sweden, and Israel. Salignostics plans to reach $70M annual revenues by 2030, through expanding its product reach, developing new saliva-based diagnostic applications, and establishing R&D and commercial collaborations with global diagnostics companies.
Funding history · 1 round · $8.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Salignostics' primary focus in diagnostic solutions?
- Salignostics specializes in developing fast, safe, user-friendly, and cost-effective saliva-based diagnostic solutions for various settings including self-testing, homecare, point-of-care, and laboratories.
- When was Salignostics founded and where is its headquarters located?
- Salignostics was founded in January 2017 and is headquartered in Jerusalem, Israel.
- What was Salignostics' most recent funding round and how much capital was raised?
- In April 2022, Salignostics completed a Series A funding round, raising a total of $8,000,000. Avigdor Orlinsky was among the investors.
- Which product did Salignostics launch in 2023 and in which markets is it available?
- In 2023, Salignostics successfully launched Salistick, the first rapid saliva-based pregnancy test. It is currently available in the UK, Sweden, and Israel.
- What are Salignostics' revenue projections for 2030?
- Salignostics plans to achieve $70 million in annual revenues by 2030 through product expansion, new diagnostic application development, and R&D and commercial collaborations.
- What is the current employee count for Salignostics?
- Salignostics currently has 11 employees.
- What is the status of Salignostics' saliva-based pregnancy test in Germany?
- Salignostics is scheduled to begin selling its saliva-based pregnancy test in Germany in December 2025.
- What new diagnostic test is Salignostics developing with Sheba?
- Salignostics is developing a saliva test for mouth cancers in collaboration with Sheba, as reported in May 2024.
- How many patents and trade secrets does Salignostics hold for its platform technology?
- Salignostics holds 4 innovative patents and 2 trade secrets covering its platform technology.